Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-11-10 DOI:10.1111/irv.70009

Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, Lorena Vega-Piris, Joan O'Donnell, Noémie Sève, Camino Trobajo-Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, Gergő Túri, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazar, Marine Maurel, Daniel Castrillejo, Charlene Bennett, Marie-Anne Rameix-Welti, Iván Martínez-Baz, Ralf Dürrwald, Adam Meijer, Aryse Melo, Beatrix Oroszi, Tove Samuelsson Hagey, Sanja Kurečić Filipović, Frederika Dijkstra, Veronica Gomez, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling, the VEBIS Primary Care Vaccine Effectiveness Group

{"title":"Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024","authors":"Lore Merdrignac, Charlotte Laniece Delaunay, Nuno Verdasca, Lorena Vega-Piris, Joan O'Donnell, Noémie Sève, Camino Trobajo-Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, Gergő Túri, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazar, Marine Maurel, Daniel Castrillejo, Charlene Bennett, Marie-Anne Rameix-Welti, Iván Martínez-Baz, Ralf Dürrwald, Adam Meijer, Aryse Melo, Beatrix Oroszi, Tove Samuelsson Hagey, Sanja Kurečić Filipović, Frederika Dijkstra, Veronica Gomez, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling, the VEBIS Primary Care Vaccine Effectiveness Group","doi":"10.1111/irv.70009","DOIUrl":null,"url":null,"abstract":"<p>We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.

Abstract Image

查看原文本刊更多论文

欧洲 VEBIS 初级医疗多中心研究：XBB.1.5 疫苗对 JN.1 世系主导期老年人无症状 SARS-CoV-2 感染的有效性，2023 年 11 月 20 日至 2024 年 3 月 1 日。

在一项欧洲多国初级医疗水平的检测阴性病例对照研究中，我们估算了 XBB.1.5 疫苗对 2023/2024 年 JN.1 世系占主导地位期间年龄≥ 65 岁的成年人感染无症状 SARS-CoV-2 的有效性 (VE)。我们根据研究地点、年龄、性别、慢性病和发病日期对 VE 进行了调整。我们纳入了 220 例病例和 1733 例对照。在接种疫苗后 1-5 周、6-11 周和≥ 12 周出现症状的人群中，VE 分别为 48%（95% CI：12-71）、23%（95% CI：-11-48）和 5%（95% CI：-92-56）。XBB.1.5疫苗对JN.1无症状感染提供短期和中度保护。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.